✦ LIBER ✦

All-Cause Mortality Rate in Patients with Idiopathic Pulmonary Fibrosis. Implications for the Design and Execution of Clinical Trials

✍ Scribed by King, Talmadge E.; Albera, Carlo; Bradford, Williamson Z.; Costabel, Ulrich; du Bois, Roland M.; Leff, Jonathan A.; Nathan, Steven D.; Sahn, Steven A.; Valeyre, Dominique; Noble, Paul W.

Book ID: 126818380
Publisher: American Thoracic Society
Year: 2014
Tongue: English
Weight: 693 KB
Volume: 189
Category: Article
ISSN: 1073-449X
DOI: 10.1164/rccm.201311-1951oc

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

[American Thoracic Society American Thor

[American Thoracic Society American Thoracic Society 2009 International Conference, May 15-20, 2009 • San Diego, California - ()] A23. ILD: OUTCOMES AND SELECTED CLINICAL ISSUES - The CAPACITY (CAP) Trials: Randomized, Double-Blind, Placebo-Controlled, Phase III Trials of Pirfenidone (PFD) in Patients with Idiopathic Pulmonary Fibrosis (IPF).

✍ Noble, P; Albera, C; Bradford, W; Costabel, U; Kardatzke, D; King, Jr, T; Sahn, 📂 Article 📅 2009 🏛 American Thoracic Society ⚖ 153 KB